Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 3 of 4 · 162 articles
AI-assisted capsule endoscopy may improve detection of Crohn’s disease lesions and reduce missed findings, which could affect diagnosis and monitoring. People with IBD may see faster or more consistent reads of capsule...
This study suggests a microbiome‑based biomarker (IgG reactivity to certain gut bacteria, especially M. gnavus) could help identify spondyloarthritis in people with Crohn’s disease and distinguish axial from peripheral...
Risk stratification helps identify people with Crohn's who are more likely to develop strictures, fistulas, or need surgery so clinicians can monitor and treat them more aggressively early on. Objective tests like fecal...
If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...
The study suggests anxiety, depression, poor sleep, and low exercise are linked with higher risk of IBD flares. That means mental health and lifestyle may be important parts of managing IBD alongside medical care.
This meta-analysis suggests people with IBD—especially those with Crohn’s disease—have a modestly increased risk of stroke. That makes cardiovascular risk assessment and prevention potentially more important for people...
Frequent routine colonoscopies after Crohn's surgery are invasive and burdensome. Using fecal calprotectin for regular monitoring could reduce unnecessary colonoscopies and detect recurrence earlier when inflammation is...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians...
A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...
A predictive model for temporary stoma could influence surgical planning for people with Crohn’s disease, helping tailor decisions and expectations around intestinal resection.
Researchers and clinicians studying Crohn’s disease want to understand whether distinct patient subgroups exist that could affect outcomes or responses. Identifying subpopulations can guide future research into...
Detecting neoplasia early is a central goal of IBD surveillance; this study suggests virtual chromoendoscopy may find more lesions than dye or white light in real-world practice, which could influence how surveillance is...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
This study maps what researchers have been publishing about Crohn's disease in children over the past decade, highlighting major topics, influential papers, and active authors/institutions.
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...
Faecal calprotectin from ileostomy output could provide a non-invasive way to detect small-bowel inflammation after surgery, helping to guide monitoring and reduce reliance on invasive tests for postoperative Crohn’s...
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Fecal calprotectin. Open the original article for the...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...
Vulvar Crohn’s is an uncommon but real extraintestinal manifestation that can cause painful skin changes and sometimes appears before GI Crohn’s is diagnosed. Knowing about it may speed diagnosis and lead to coordinated...
Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response...
This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...
This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...
This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
Knowing the type of Crohn’s disease helps explain where symptoms come from and what treatments or procedures might be considered. The article links specific symptoms and complications to each anatomical pattern of...
A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...
Based on the title and source metadata, this appears to be a biomarker study related to Colorectal cancer and Tests and monitoring. The original article is from msn.com.
Based on the title and source metadata, this appears to be a patient education related to Tests and monitoring. The original article is from msn.com.
Cure8 found this source from newsx.com, but the page could not be read reliably yet. It is tagged for Colorectal Cancer Risk and Tests and monitoring. Open the original article for the full details.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
